Recurrent Ovarian Cancer
Conditions
Keywords
second line, platinum sensitive, first line bevacizumab, biologic factors, clinical factors
Brief summary
Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab. Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined. This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.
Interventions
DRUGBevacizumab
DRUGPaclitaxel
DRUGCarboplatin
DRUGpegylated liposomal doxorubicin
DRUGGemcitabine
Sponsors
Mario Negri Institute for Pharmacological Research
National Cancer Institute, Naples
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients ≥18 years of age. * Patients with histologically confirmed epithelial ovarian or fallopian tube carcinoma or primary peritoneal carcinoma, including mixed Mullerian Tumours * Recurrence or progression at least 6 months after the last chemotherapy cycle of a first line carboplatin + paclitaxel chemotherapy including bevacizumab (recurrence or progression might occur either during or after bevacizumab as maintenance) * Patients can be included if they have a RECIST progression, with either measurable or non-measurable disease * ECOG (Eastern Cooperative Oncology Group Performance) Status of 0-2. * Life expectancy of at least 12 weeks. * Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements including blood samples for molecular analyses. * Availability of tumour samples for molecular analyses from primary surgery (mandatory) and secondary surgery (when available)
Exclusion criteria
Cancer related * Ovarian tumours with low malignant potential (i.e. borderline tumours) * History or evidence of synchronous primary endometrial carcinoma, unless all of the following criteria related to the endometrial carcinoma are met: * stage ≤Ia * no more than superficial myometrial invasion * no lymphovascular invasion * not poorly differentiated (grade 3 or papillary serous or clear cell carcinoma). * Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer. Prior current or planned treatment: * More than one previous chemotherapy line * Previous therapy with other anti-angiogenetic agents different from bevacizumab. * Any prior radiotherapy to the pelvis or abdomen. * Surgery (including open biopsy) within 4 weeks prior to the first bevacizumab dose.Current or recent (within 10 days prior to the first study drug dose) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes (except for line patency, in which case international normalized ratio \[INR\] must be maintained below 1.5). Post operative prophylaxis with low molecular weight heparin sc is allowed. * Current or recent (within 30 days of first study dosing) treatment with any other investigational drug. Laboratory: * Inadequate bone marrow function: ANC (absolute neutrophil count): \<1500/mm3, or platelet count \<100,000/mm3 or Haemoglobin \<9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9 g/dl. * Inadequate coagulation parameters: * activated partial thromboplastin time (APTT) \>1.5 x upper limit of normal (ULN) or * INR (international normalized ratio) \>1.5 * Inadequate liver function, defined as: * serum (total) bilirubin \>1.5 x ULN for the institution * AST/SGOT or ALT/SGPT \> 2.5 x ULN. * Inadequate renal function, defined as: * serum creatinine \>2.0 mg/dl or \>177 micromol/l * urine dipstick for proteinuria \>2+. Patients with ≥ 1+ proteinuria at baseline dipstick analysis should undergo a 24-hour urine collection and must demonstrate ≤1g of protein in their 24-hour urine collection. Prior or concomitant conditions or procedures: * History or evidence of brain metastases or spinal cord compression. * Pregnant or lactating females. * History or evidence of thrombotic or haemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or sub-arachnoid haemorrhage within ≤6 months prior to the first study treatment). * Uncontrolled hypertension (sustained systolic \>150 mm Hg and/or diastolic \>100 mm Hg despite antihypertensive therapy) or clinically significant (i.e. active) cardiovascular disease, including: * myocardial infarction or unstable angina within ≤6 months prior to the first study treatment * New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF) * serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia) * peripheral vascular disease ≥grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision). * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess, or with signs of impending bowel obstruction within 6 months prior to the first study treatment. * Non-healing wound, ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require three weekly wound examinations. * Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | 12 months | assessed by local Investigator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 12 months | — |
| number of complete or partial responses | 6 months | according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| worst grade toxicity per patient | evaluated every 3 weeks up to 12 months | according to Common Toxicity Criteria for Adverse Events v. 4.03 |
| number of patients taking antithrombotic therapy | at baseline | — |
| progression free survival | 12 months | as measured by independent central review |
| number of patients taking oral antidiabetic therapy | at baseline | — |
Other
| Measure | Time frame |
|---|---|
| predictive clinical factors for efficacy of bevacizumab | 12 months |
| correlation of baseline plasma biomarker expression and clinical outcome | 12 months |
Countries
France, Greece, Italy, Monaco, Switzerland
Outcome results
None listed